Research

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for November 2023.

Representatives of the EAN Guideline Production Group participated in the GIN 2023 conference in Glasgow, presenting the EAN's Guideline Prioritisation Process.

Prof. Claudio Bassetti and Dr Marina Τüzün presented the design of the Burden of Sleep/Wake Disorders: Excessive Daytime Sleepiness and Insomnia project and the initial results of the pilot study currently taking place in Bern.

Our Paper of the Month for October 2023 is a multicentre, prospective, randomised clinical trial investigating whether transdermal nicotine may have a disease-modifying effect in early, therapy-naïve Parkinson's disease.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for October 2023.

The European Medicines Agency (EMA) is looking for new data partners to collaborate with DARWIN EU® - the Data Analysis and Real-World Interrogation Network.

The EAN is pleased to announce the creation of a new Coordinating Panel on Functional Neurological Disorders. All EAN Individual Members with an interest in this field are encouraged to apply!

Our paper of the month presents the results of a randomised trial assessing AXER-204, a soluble decoy fragment of NgR1 able to block the action of three inhibitors of the axonal growth in individuals with chronic traumatic cervical SCI.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for September 2023.

The EAN is looking for a candidate who will provide support to the EAN Guideline Production Group and Guideline Taskforces as a Junior Methodologist.

Our paper of the month is a phase 3, double-blind, multicentre, trial investigating the efficacy and the safety of vorasidenib, a dual inhibitor of the IDH1 and IHD2 enzymes, in patients with residual or recurrent IDH mutant grade 2 gliomas.

Each month the EANpages editorial team reviews the scientific press for recently published papers of outstanding interest to neurologists. Here we present our selection for July 2023.

Help increase awareness of brain-injury-specific commonalities for a chance to win free registration for EAN 2024.

Please take this survey, even if you currently do not have access to genetic testing, and help ILAE establish the state of genetic testing worldwide.

This month we have selected two papers of the month, reporting the results of two randomised, double-blind, placebo-controlled, phase III trials investigating potential therapies for generalised Myasthenia Gravis.